hepatitis b n.
Skip this Video
Download Presentation
Hepatitis B

Loading in 2 Seconds...

play fullscreen
1 / 15

Hepatitis B - PowerPoint PPT Presentation

  • Uploaded on

Hepatitis B. Epidemiology. HBV infection acquired early in life is a major cause of chronic liver disease, including cirrhosis, and primary liver cancer The hepatitis B virus is the 2 nd most important known human carcinogen, after tobacco

I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
Download Presentation

PowerPoint Slideshow about 'Hepatitis B' - mizell

Download Now An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.

- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
  • HBV infection acquired early in life is a major cause of chronic liver disease, including cirrhosis, and primary liver cancer
  • The hepatitis B virus is the 2nd most important known human carcinogen, after tobacco
  • Up to 400 million people, mostly in the Asia Pacific region, are chronically HBV– infected
  • There is currently an epidemic of chronic Hepatitis B in Australia
  • In Australia up to 160,000 are chronically infected with HBV – half are from endemic countries of the Asia Pacific region
  • Unlike HIV and Hep C (sexy infections) there is no comprehensive national Hepatitis B public health strategy
  • Universal hepatitis B vaccination for infants and people at high risk of infection has been implemented in Australia since 2000
at risk groups in australia
At Risk Groups in Australia
  • IV drug users (16% of prevalence but 40% of all new acute cases. Usually co-infected with hepatitis C increasing risk of chronic illness and advanced liver disease)
  • People born in an endemic region
    • Asia and the Pacific Islands (50% of prevalence)
    • Africa, the Middle East, and the Mediterranean region
  • Homosexual men (8%)
  • Indigenous - the virus was discovered in 1965 in Australian aborigines. They make up 2% of the total population but 16% of the total prevalence of chronic hepatitis B.
  • Prisoners
transmission of hbv
Transmission of HBV
  • Saliva, semen, blood
  • Perinatal – risk of disease is 80% from mother +ve to HBsAg and HNeAg
  • To children through household contact
  • In healthcare settings and sharing of contaminated equipment
  • Hep B is a DNA virus and uses reverse transcription to copy its DNA
  • The virus does not kill cells but expression of antigens causes both cytotoxic CD8+ T cell lysis (minor defence) and secretion of cytokines (IFN-γ and TNF-α ) causing non-cytolytic viral inhibition (major defence) see http://www.jimmunol.org/content/184/1/287
  • The antigens expressed by infected hepatocytes are:
    • Surface antigen
    • Core antigen
    • E antigen (a soluble protein secreted by the virus into the bloodstream)
acute hbv infection clinical
Acute HBV Infection - Clinical
  • Symptoms: primarily jaundice after 8 weeks (range 6-12 weeks) but other symptoms can appear such as malaise, nausea, vomiting, LOA, arthralgia, myalgia
  • Serological markers
    • HBV DNA early marker (2 weeks after infection)
    • HBs-Ag can be detected 1 month after infection
    • anti-HBc IgM and Hbe-Ag at 8 weeks
  • LFT’s: ALT, AST
  • Mortality is 1%
chronic hbv infection clinical
Chronic HBV Infection - Clinical
  • Defined clinically by serological markers: HBs-Ag persisting for longer than 6 months
  • Other markers are usually variable
phases of chronic hbv infection
Phases of Chronic HBV Infection
  • Immune tolerant phase: the immune system doesn’t recognise surface or e antigens and a high viral load (high HBV DNA) persisting for 20-30 years if infected perinatally or during childhood
  • HBeAg clearance phase: development of anti-Hbe (Hbe-Ag seroconversion) and development of immune response causing:
    • Liver inflammation, raised LFT’s
    • Flare-ups causing jaundice
    • Progression of liver disease to possible advanced liver disease if high viral load HBV DNA > 100,000 IU/mL
  • Low/non replicative phase: almost complete eradication of the virus with normal LFT’s and low HBV DNA, minimal liver damage and low risk of developing advanced live disease
  • Reactivating phase: immunosuppression typically is the cause of reactivation of the infection, inflammation and raised ALT/AST with increasing HBV DNA but no return of Hbe-Ag. Advance liver disease can develop if HBV DNA is > 100,000 IU/mL
treatment of hep b
Treatment of Hep B
  • The targets of treatment are:
    • Inhibit viral DNA replication
    • Enhance the immune response (as already mentioned, the main immune response is the non-cytolytic one involving cytokines)
ongoing treatment
Ongoing Treatment
  • Medicare only pays for monotherapy, which is suboptimal - cf successful combination therapies subsidised for “sexier” Hep C and HIV
  • Nucleoside monotherapy has been associated with development of resistance
  • LFT’s and serology are performed every 3 months to determine effectiveness of treatment (not covered by Medicare)